Psilocybin and Neuroplasticity: How Mushrooms Rewire the Brain

Beyond Mood: Structural Brain Changes

The conventional understanding of psilocybin focuses on its acute psychological effects — the hours-long experience of altered consciousness, emotional processing, and mystical states. But the most scientifically significant finding of the past five years is not what psilocybin does during the experience. It is what it does to the brain's physical structure in the days and weeks after.

Neuroplasticity — the brain's ability to form new synaptic connections and reorganise its network architecture — is the mechanism through which all learning, recovery, and adaptation occurs. Depression, PTSD, addiction, and chronic stress all reduce neuroplasticity. Psilocybin appears to dramatically increase it.

The Synaptogenesis Finding

The landmark study was published in Neuron in 2021 by Ly et al. at UC Davis. Using mouse models, the researchers found that a single dose of psilocybin produced a 10% increase in dendritic spine density in the prefrontal cortex within 24 hours — and that this increase persisted for at least one month. Dendritic spines are the physical sites of synaptic connections: more spines means more connections means greater neural flexibility.

Crucially, the increase in dendritic spines correlated with improvements in stress-related behaviours. Mice that had been subjected to chronic stress (which reduces dendritic spine density) showed restoration of both spine density and normal behaviour after a single psilocybin dose. The effect was comparable to ketamine — another rapid-acting treatment for depression — but longer-lasting.

A 2023 follow-up study in Science by Bhatt et al. used two-photon microscopy to image individual dendritic spines in living mice before and after psilocybin administration. They found that psilocybin not only increased spine density but preferentially strengthened specific synaptic connections — suggesting that the neuroplasticity effect is not random but is shaped by the content of the experience during the drug period.

Network Rewiring in Humans

The human neuroimaging evidence comes primarily from fMRI studies examining brain network connectivity before and after psilocybin therapy. The 2022 Nature Medicine study by Daws et al. at Imperial College London is the most comprehensive. Using fMRI in 60 patients receiving psilocybin therapy for depression, they found that psilocybin produced lasting increases in brain network flexibility — measured as the degree to which brain regions switched between different functional networks over time.

This flexibility increase was not present in the escitalopram comparison group, and it correlated directly with antidepressant response: patients who showed greater network flexibility after psilocybin showed greater reductions in depression scores. The effect persisted at 6-month follow-up.

A separate 2021 study by Carhart-Harris et al. found that psilocybin therapy produced lasting increases in connectivity between the default mode network (DMN) and other brain networks — essentially breaking down the rigid, self-referential processing loop that characterises depression. This increased inter-network connectivity was not seen after SSRI treatment.

BDNF: The Molecular Mechanism

Brain-derived neurotrophic factor (BDNF) is a protein that promotes the growth and maintenance of neurons and synapses. It is sometimes called "fertiliser for the brain." Depression, chronic stress, and ageing all reduce BDNF levels; exercise, antidepressants, and — most potently — psilocybin all increase them.

A 2021 study in ACS Chemical Neuroscience found that psilocybin and related psychedelics activate TrkB receptors (the primary BDNF receptor) at concentrations far below those needed to activate serotonin receptors — suggesting that BDNF signalling may be a primary rather than secondary mechanism of psilocybin's neuroplastic effects. This finding has significant implications: it means that even sub-psychedelic doses of psilocybin (i.e., microdoses) may produce neuroplasticity effects through BDNF signalling.

What This Means Practically

The neuroplasticity research reframes psilocybin from a "drug that makes you feel better" to a "tool that changes the brain's capacity to change." This distinction matters because it explains why psilocybin effects persist long after the drug has cleared the system, why the therapeutic set and setting matter (the brain is forming new connections shaped by the content of the experience), and why psilocybin may work for conditions that have not responded to treatments that only modulate neurochemistry without changing network architecture.